Edition:
United Kingdom

Regeneron Pharmaceuticals Inc (REGN.OQ)

REGN.OQ on NASDAQ Stock Exchange Global Select Market

312.56USD
24 May 2019
Change (% chg)

$-2.70 (-0.86%)
Prev Close
$315.26
Open
$316.66
Day's High
$318.79
Day's Low
$308.51
Volume
144,019
Avg. Vol
276,562
52-wk High
$442.00
52-wk Low
$291.79

Select another date:

Sat, Apr 27 2019

FDA approves expanded label for Regeneron/Sanofi's cholesterol drug

The U.S. Food and Drug Administration on Friday approved Regeneron Pharmaceuticals Inc's cholesterol drug Praluent as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.

UPDATE 1-U.S. FDA approves expanded label for Regeneron/Sanofi's cholesterol drug

April 26 The U.S. Food and Drug Administration on Friday approved Regeneron Pharmaceuticals Inc's cholesterol drug Praluent as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.

U.S. FDA approves expanded label for Regeneron's cholesterol drug

April 26 The U.S. Food and Drug Administration on Friday approved Regeneron Pharmaceuticals Inc's cholesterol drug Praluent, as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.

Regeneron forays into gene-silencing therapies with Alnylam tie-up

Regeneron Pharmaceuticals Inc said it would invest $800 million in Alnylam Pharmaceuticals Inc to develop treatments for eye and central nervous system diseases using gene-silencing RNA interference (RNAi) technology.

UPDATE 2-Regeneron forays into gene-silencing therapies with Alnylam tie-up

April 8 Regeneron Pharmaceuticals Inc said it would invest $800 million in Alnylam Pharmaceuticals Inc to develop treatments for eye and central nervous system diseases using gene-silencing RNA interference (RNAi) technology.

Alnylam, Regeneron to partner for RNAi treatments

April 8 Alnylam Pharmaceuticals Inc and Regeneron Pharmaceuticals Inc on Monday agreed to partner to develop treatments for eye and central nervous system diseases using RNA interference.

Regeneron/Sanofi wins U.S. approval for expanded use of skin drug

The U.S. Food and Drug Administration said it approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged between 12 and 17, a boost for both the companies in the world's largest market for drugs.

UPDATE 2-Regeneron/Sanofi wins U.S. approval for expanded use of skin drug

March 11 The U.S. Food and Drug Administration said it approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged between 12 and 17, a boost for both the companies in the world's largest market for drugs.

Regeneron/Sanofi skin disease drug cleared for use in U.S. teens

March 11 The U.S. Food & Drug Administration on Monday approved use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent for adolescents aged 12 and older, helping expand the use of an important revenue driver for both the companies in the world's largest market for drugs.

Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug

Biotech company Amgen Inc said on Monday a U.S. jury confirmed the validity of patents on its cholesterol drug Repatha, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA.

Select another date: